Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

230
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
230

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Infusion of human mesenchymal stromal cells during normothermic machine perfusion of porcine kidneys: a randomized, blinded, preclinical study.

Scientific reports·2026
Same author

High-yield, standardised automated radiosynthesis process for routine clinical insulinoma PET with [⁶⁸Ga]Ga-NODAGA-exendin-4.

EJNMMI radiopharmacy and chemistry·2026
Same author

Pharmacokinetics and dosimetry of radiolabeled FAP-targeting single-domain antibody 4AH29 in Göttingen minipigs.

Nuclear medicine and biology·2026
Same author

Long-term follow-up of the transplant-eligible cohort of the EMN12/HOVON-129 study for primary plasma cell leukemia patients.

Blood cancer journal·2026
Same author

Characterizing the Fate of Anti-CS1 Nanobody Displaying Extracellular Vesicles in Multiple Myeloma.

Journal of extracellular vesicles·2026
Same author

Automated and manual synthesis of [<sup>68</sup>Ga]Ga-DOTA-4AH29 intended for PET-imaging of FAP-expression.

EJNMMI radiopharmacy and chemistry·2026

Related Experiment Video

Updated: Sep 4, 2025

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

6.9K

Radiotheranostic Agents in Hematological Malignancies.

Jo Caers1,2, Elodie Duray1,3, Louise Vrancken1,2

  • 1Laboratory of Hematology, GIGA I³, University of Liège, Liège, Belgium.

Frontiers in Immunology
|July 22, 2022
PubMed
Summary

Radioimmunotherapy (RIT) uses targeted antibodies and radiation for cancer treatment. Newer theranostic agents offer improved targeting and personalized medicine for hematological malignancies.

Keywords:
leukemialymphomamultiple myelomaradionuclideradiotheranostic

More Related Videos

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.5K
Author Spotlight: Radiotherapy and Clonogenic Assays for Advancing Cancer Research and Personalized Medicine
05:39

Author Spotlight: Radiotherapy and Clonogenic Assays for Advancing Cancer Research and Personalized Medicine

Published on: April 5, 2024

940

Related Experiment Videos

Last Updated: Sep 4, 2025

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

6.9K
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.5K
Author Spotlight: Radiotherapy and Clonogenic Assays for Advancing Cancer Research and Personalized Medicine
05:39

Author Spotlight: Radiotherapy and Clonogenic Assays for Advancing Cancer Research and Personalized Medicine

Published on: April 5, 2024

940

Area of Science:

  • Oncology
  • Nuclear Medicine
  • Immunotherapy

Background:

  • Radioimmunotherapy (RIT) combines radiation therapy with monoclonal antibodies (Abs) for cancer treatment.
  • Despite early introduction for non-Hodgkin lymphoma, RIT has had limited clinical application.
  • Recent advancements focus on theranostic agents using antibody fragments or mimetics for improved tumor targeting.

Purpose of the Study:

  • To review strategies for noninvasive detection and treatment of hematological malignancies using radiopharmaceuticals.
  • To discuss the evolution and future applications of radiotheranostic agents in personalized medicine.

Main Methods:

  • Review of scientific literature on radiopharmaceuticals and theranostic agents.
  • Analysis of strategies for improving specificity and pharmacokinetics.
  • Discussion of advancements in antibody fragments, peptides, affibodies, and single-chain Abs.

Main Results:

  • Development of theranostic agents combining diagnostic and therapeutic capabilities via radionuclide conjugation.
  • Trend towards increased specificity, faster pharmacokinetics, and personalized medicine approaches.
  • Emergence of novel agents like antibody fragments and small mimetics for enhanced tumor targeting.

Conclusions:

  • Radiotheranostic agents represent a significant advancement in treating hematological malignancies.
  • Future applications hold promise for more personalized and effective cancer therapies.
  • Continued research into novel agents and strategies is crucial for clinical translation.